Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study

It is known from previous literature that type II Spinal Muscular Atrophy (SMA) patients generally, after the age of 5 years, presents a steep deterioration until puberty followed by a relative stability, as most abilities have been lost. Although it is possible to identify points of slope indicatin...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 5; p. e0267930
Main Authors Coratti, Giorgia, Lenkowicz, Jacopo, Patarnello, Stefano, Gullì, Consolato, Pera, Maria Carmela, Masciocchi, Carlotta, Rinaldi, Riccardo, Lovato, Valeria, Leone, Antonio, Cesario, Alfredo, Mercuri, Eugenio
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 05.05.2022
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It is known from previous literature that type II Spinal Muscular Atrophy (SMA) patients generally, after the age of 5 years, presents a steep deterioration until puberty followed by a relative stability, as most abilities have been lost. Although it is possible to identify points of slope indicating early improvement, steep decline and relative stabilizations, there is still a lot of variability within each age group and it's not always possible to predict individual trajectories of progression from age only. The aim of the study was to develop a predictive model based on machine learning using an XGBoost algorithm for regression and report, explore and quantify, in a single centre longitudinal natural history study, the influence of clinical variables on the 6/12-months Hammersmith Motor Functional Scale Expanded score prediction (HFMSE). This study represents the first approach to artificial intelligence and trained models for the prediction of individualized trajectories of HFMSE disease progression using individual characteristics of the patient. The application of this method to larger cohorts may allow to identify different classes of progression, a crucial information at the time of the new commercially available therapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have read the journal’s policy and have the following competing interests: GC, MCP, and EM received personal fees from BIOGEN, ROCHE, AVEXIS/NOVARTIS for activities such as consultancies, advisory boards, and steering committees outside the submitted work. VL is a paid employee of Roche Italia. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0267930